Study to Evaluate the Safety, PK, and Pharmacodynamics of LIB003

Summary

Randomized, double-blind, placebo-controlled, single ascending dose study in nine (9) separate and sequential dose cohorts (7 SC and 2 IV cohorts) to assess the safety and tolerability, pharmacokinetics and pharmacodynamics of LIB003 in subjects with moderately elevated LDL-C levels.

Timeline

Start

2017-10-30

Primary completion

2018-05-30

Completion

2018-06-30

Drugs

Indications